Brachytherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Seeds, Applicators & Afterloaders, Electronic Brachytherapy), By Application (Prostrate Cancer, Gynecological Cancer, Breast Cancer, Others), By Dosage Type (High-Dose Rate (HDR), Low-Dose Rate (LDR)), By Region, By Competition, 2020-2030F

Market Overview

The Global Brachytherapy Market, valued at USD 1.06 Billion in 2024, is projected to experience a CAGR of 7.40% to reach USD 1.63 Billion by 2030. Brachytherapy is a specialized form of internal radiation therapy involving the precise placement of encapsulated radioactive sources directly within or immediately adjacent to a target tumor volume. This highly localized treatment delivers potent radiation doses while minimizing exposure to surrounding healthy tissues, thereby improving treatment efficacy and patient outcomes. The market's growth is primarily driven by the increasing global prevalence of various cancers, necessitating effective and minimally invasive therapeutic options, along with brachytherapy's inherent advantages such as targeted radiation delivery, improved local tumor control, and potentially shorter treatment durations. According to the World Health Organization and the International Agency for Research on Cancer, in 2022, there were an estimated 20 million new cancer cases globally.

A significant impediment to market expansion remains the substantial initial capital investment required for specialized equipment and facilities, coupled with the critical need for a highly skilled workforce proficient in brachytherapy planning and delivery.

Key Market Drivers

The global brachytherapy market is significantly influenced by the increasing worldwide cancer burden. As cancer incidence continues its upward trajectory across various demographics, the demand for effective, localized treatment modalities like brachytherapy intensifies. According to the International Agency for Research on Cancer's Global Cancer Observatory, in February 2024, prostate cancer was the fourth most commonly occurring cancer worldwide with 1.5 million new cases in 2022. This substantial and growing caseload drives healthcare providers to seek therapies that offer high rates of local control and improved patient outcomes, directly expanding the addressable patient population for brachytherapy applications.

Further propelling market growth are ongoing advancements in brachytherapy technologies. Innovations encompassing enhanced imaging guidance, sophisticated treatment planning software, and novel applicator designs permit greater precision in radioactive source placement, thereby maximizing dose delivery to tumors while minimizing exposure to healthy tissues. For instance, according to UroToday. com, in October 2023, an analysis presented at the American Society for Therapeutic Radiation Oncology (ASTRO) 65th Annual Meeting demonstrated that a study evaluating single dose versus fractionated high-dose rate brachytherapy in localized prostate cancer included 293 patients, showcasing continuous efforts to refine treatment protocols. These technological developments lead to safer procedures, reduced side effects, and expanded indications for brachytherapy, reinforcing its role as a vital component of comprehensive cancer care. The sustained rise in conditions treatable by brachytherapy further underscores market expansion; according to Forbes, in September 2025, "Prostate Cancer Rates In U. S. Increased Each Year From 2014 To 2024", the rates of prostate cancer in the U. S. increased by around 3% each year.

Download Free Sample Report

Key Market Challenges

The substantial initial capital investment required for specialized equipment and facilities, coupled with the critical need for a highly skilled workforce, represents a significant impediment to the global brachytherapy market's expansion. This financial barrier limits the establishment of new brachytherapy centers and constrains existing facilities from upgrading to advanced technologies. The specialized nature of brachytherapy necessitates considerable upfront expenditure for afterloaders, treatment planning systems, and dedicated shielded rooms, presenting a challenging economic hurdle for healthcare providers aiming to integrate or enhance this treatment modality.

Furthermore, a shortage of professionals proficient in brachytherapy planning and delivery significantly hampers market growth. This includes radiation oncologists, medical physicists, and radiation therapists with specialized brachytherapy expertise. According to the Royal College of Radiologists, in 2024, the United Kingdom experienced a 15% shortfall of clinical oncologists, a key part of the brachytherapy team, illustrating a regional facet of this global workforce constraint. This deficit limits treatment capacity, extends patient waiting periods, and impacts the consistent delivery of high-quality brachytherapy services, directly restraining the market by restricting patient access and operational capabilities.

Key Market Trends

The emergence of artificial intelligence in brachytherapy treatment planning is significantly advancing the market by enhancing precision and efficiency. AI algorithms are streamlining complex tasks such as organ at risk contouring and dose optimization, which traditionally required considerable manual effort. The European Society for Radiotherapy and Oncology Congress Report from 2024 highlighted how AI-driven auto-segmentation reduced delineation time by half in cervical cancer brachytherapy and substantially decreased overall planning times with systems like BiCycle. According to Elekta, in May 2024, the company launched Elekta Evo, a CT-Linac with AI-enhanced imaging and its Elekta ONE Planning software, featuring AI-driven automation for contouring and dose planning across various radiation therapy modalities. This integration of AI leads to more consistent and accurate treatment plans, ultimately improving patient outcomes and workflow efficiency in clinical settings.

Another pivotal trend is the greater integration of brachytherapy in multimodal cancer treatments, reflecting a strategic shift towards comprehensive and individualized patient care. Brachytherapy is increasingly combined with other modalities, such as external beam radiation therapy, chemotherapy, or surgery, to achieve superior local control and overall survival rates, particularly in advanced or high-risk cancers. A November 2023 Surveillance, Epidemiology, and End-Results study on cervical cancer in the U. S. indicated that 64% of the 8,500 women received brachytherapy in combination with external beam radiation therapy. Furthermore, according to the Johns Hopkins Kimmel Cancer Center, in March 2024, high-dose rate brachytherapy for prostate cancer was increasingly being utilized either as a standalone treatment or in combination with external beam radiation techniques like intensity-modulated radiation therapy or proton therapy for high-risk or locally advanced disease. This collaborative approach maximizes therapeutic benefits by leveraging the strengths of each treatment method.

Segmental Insights

The Breast Cancer segment is experiencing rapid growth within the Global Brachytherapy Market, driven by its distinct advantages as a targeted and efficient treatment modality. This accelerated expansion is primarily attributed to the increasing global incidence of breast cancer, which necessitates effective and less invasive therapeutic options. Brachytherapy offers highly localized radiation delivery directly to the tumor site, thereby minimizing radiation exposure to adjacent healthy tissues and critical organs such as the heart and lungs. Furthermore, the adoption of Accelerated Partial Breast Irradiation (APBI) techniques using brachytherapy significantly reduces overall treatment duration compared to conventional external beam radiation, often completing a course in just five days, which enhances patient convenience and improves cosmetic outcomes, particularly after lumpectomy. This precise, time-efficient approach positions brachytherapy as a preferred option for appropriate breast cancer cases.

Regional Insights

North America leads the global brachytherapy market due to a combination of factors. The region demonstrates a high incidence of various cancers, including prostate and breast cancer, which are effectively treated with brachytherapy. This is complemented by an advanced healthcare infrastructure featuring specialized cancer treatment centers. Furthermore, North America benefits from ongoing technological advancements, fostering innovative brachytherapy solutions. Favorable regulatory and reimbursement landscapes, supported by bodies like the Centers for Medicare & Medicaid Services, also facilitate broader adoption and investment in these treatments. Increased awareness among patients and healthcare professionals regarding brachytherapy's benefits further solidifies the region's market position.

Recent Developments

• In October 2025, OncoSil Medical Limited announced the first patient treatment in Germany using its OncoSil™ brachytherapy device. This milestone marked the commencement of the company's commercial activities in the German market, a significant development for the global brachytherapy sector. The OncoSil™ device is designed for the treatment of locally advanced unresectable pancreatic cancer, a challenging malignancy. The successful application at Universitätsklinikum Augsburg, a leading oncology center, demonstrated the device's clinical utility and initiated its availability to patients in one of Europe’s largest healthcare markets.

• In June 2025, BEBIG Medical launched its SagiNova Brachytherapy System at DEGRO 2025 in Europe. This introduction marked a significant advancement in radiation therapy for prostate cancer treatment within the global brachytherapy market. The SagiNova system aimed to provide enhanced capabilities for high-dose-rate (HDR) brachytherapy, allowing for precise and targeted radiation delivery. This new product launch by BEBIG Medical underscored the company's commitment to innovation in cancer care and its efforts to expand its footprint by offering advanced solutions to healthcare providers. The system's features were designed to improve treatment accuracy and patient outcomes for those undergoing brachytherapy.

• In January 2025, CIVCO Medical Solutions introduced its new TP Pivot Pro™ Needle Guide. This product launch within the global brachytherapy market aimed to facilitate a minimally invasive approach for ultrasound-guided transperineal prostate biopsies, thereby enhancing procedural efficiency for medical professionals. The needle guide is designed to improve the precision and ease of seed placement during brachytherapy procedures for prostate cancer. This innovation reflects CIVCO Medical Solutions' continuous efforts to develop advanced equipment and devices that support the diagnosis and treatment of prostate cancer, ultimately benefiting patient care through more accurate and efficient interventions.

• In May 2024, GT Medical Technologies, Inc. announced a strategic distribution partnership with Theragenics Corporation. This collaboration focused on expanding physician access to Cesium-131 seeds, which are critical for various non-brain cancer-related brachytherapy treatments, including prostate cancer. Under the agreement, Theragenics became the exclusive distributor for Cesium-131 brachytherapy seeds and carriers. GT Medical Technologies, the sole manufacturer of Cesium-131, maintained its focus on advancing its FDA-cleared GammaTile therapy for operable brain tumors in the U.S. This partnership aimed to ensure continued availability of Cesium-131 for clinicians and patients, addressing essential healthcare needs within the global brachytherapy market.

Key Market Players

• Varian Medical Systems, Inc.
• Becton Dickinson & Company
• Elekta AB
• Isoray Medical, Inc.
• Eckert & Ziegler BEBIG
• iCAD, Inc.
• CIVCO Medical Solutions
• Theragenics Corporation
• Argon Medical Devices, Inc.
• Carl Zeiss Meditec AG

Report Scope:

In this report, the Global Brachytherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Brachytherapy Market, By Product:

o   Seeds

o   Applicators & Afterloaders

o   Electronic Brachytherapy

• Brachytherapy Market, By Application:

o   Prostate Cancer

o   Gynecological Cancer

o   Breast cancer

o   Others

• Brachytherapy Market, By Dosage Type:

o   High-Dose Rate (HDR)

o   Low-Dose Rate (LDR)

• Brachytherapy Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Brachytherapy Market.

Available Customizations:

Global Brachytherapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Brachytherapy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]